Mupadolimab

Summary

Mupadolimab (CHEMBL4802200) is a phase-3 clinical-stage antibody targeting NT5E; indicated across 4 conditions including severe acute respiratory syndrome and neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Targets: 1 (NT5E)
• Indications: 4 conditions
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4802200
Name	Mupadolimab
Type	Antibody
Max phase	3

Also known as: Cpi-006, CPI-006, CPI006, CPX-006, Mupadolimab, MUPADOLIMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
NT5E	Ecto-5’-Nucleotidase	Inhibition	8.15	0%	P21589

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): NT5E.

Top Reactome pathways

14 total, by targets touching each:

Pathway	Targets	Genes
Metabolism	1	NT5E
Metabolism of nucleotides	1	NT5E
Disease	1	NT5E
Nicotinate metabolism	1	NT5E
Metabolism of water-soluble vitamins and cofactors	1	NT5E
Metabolism of vitamins and cofactors	1	NT5E
Infectious disease	1	NT5E
Pyrimidine catabolism	1	NT5E
Purine catabolism	1	NT5E
Nucleotide catabolism	1	NT5E
Leishmania infection	1	NT5E
Purinergic signaling in leishmaniasis infection	1	NT5E
Cell recruitment (pro-inflammatory response)	1	NT5E
Parasitic Infection Pathways	1	NT5E

Dominant GO biological processes

GO term	Targets
AMP catabolic process	1
DNA metabolic process	1
leukocyte cell-cell adhesion	1
response to ATP	1
ADP catabolic process	1
ATP metabolic process	1
adenosine biosynthetic process	1
negative regulation of inflammatory response	1
calcium ion homeostasis	1
inhibition of non-skeletal tissue mineralization	1
nucleotide catabolic process	1

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
neoplasm	1	MONDO:0005070	EFO:0000616
infectious disease	1	MONDO:0005550	EFO:0005741

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE1	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04734873	PHASE3	TERMINATED	CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients
NCT03454451	PHASE1	COMPLETED	CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
NCT04464395	PHASE1	COMPLETED	Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

7 molecules share ≥1 primary target. Top 7 by shared-target count:

Molecule	Source	Status	Shared targets
FLUDARABINE	ChEMBL + PubChem	Phase 3 (approved)	NT5E
QUERCETIN	ChEMBL + PubChem	Phase 3 (approved)	NT5E
ELLAGIC ACID	ChEMBL	Phase 2	NT5E
FTIVAZIDE	ChEMBL	Phase 2	NT5E
QUEMLICLUSTAT	ChEMBL	Phase 2	NT5E
adenosine	PubChem	Approved	NT5E
Tiamulin	PubChem	Approved	NT5E